---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-213472"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:08:32.477926+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioAge Labs Q1 net loss $22.3M; positive Phase 1 data for BGE-102 NLRP3 inhibitor

## Summary
- Net loss $22.3M ($0.52 diluted EPS) vs $12.9M ($0.36) in Q1 2025; R&D spend rose to $20.4M.
- Positive Phase 1 data for oral NLRP3 inhibitor BGE-102: median hsCRP reduction 86%, 87-93% reached normalized hsCRP <2 mg/L.
- Ph2 dose-ranging trial in CVD risk and Ph1b/2a in diabetic macular edema both planned to start mid-2026.
- Cash, equivalents & securities $384.9M as of Mar 31, 2026; funded through 2029.
- Completed upsized follow-on offering for $132.3M in gross proceeds in early 2026.

## SEC filing metadata
- accession: 0001193125-26-213472
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000119312526213472/0001193125-26-213472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000119312526213472/bioa-20260508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-213472
- JSON: https://secwatch.observer/filing/0001193125-26-213472.json
- Plain text: https://secwatch.observer/filing/0001193125-26-213472.txt

## Source-grounded claims
- claim_id: 81a94f7dde897c8f96477f90afb90c857ee9fa5d
  claim: BioAge Labs, Inc. reported first quarter ended March 31, 2026 results: revenue 2.8 million, net income -22.3 million, EPS -0.52.
  evidence_excerpt: with Lilly ExploR&D for the development of therapeutic antibodies targeting novel metabolic aging targets. First Quarter 2026 Financial Results Collaboration revenue was $2.8 million for the quarter ended March 31, 2026, compared to $1.5 million for the same period in 2025. The $1.3 million increase in collaboration revenue was due to increased full-time
  evidence_url: https://www.sec.gov/Archives/edgar/data/1709941/000119312526213472/0001193125-26-213472-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.